Inside the research
Cardinal Health, Inc.
CAH Research profile · latest available data
Price overview
$220.22
▼ -2.40 (-1.1%)
| 52w hi | $248.61 |
|---|---|
| 52w lo | $147.43 |
| Vol | 2.09M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.09
| Short | -0.11 |
|---|---|
| Medium | +0.22 |
| Long | +0.22 |
computed 2026-09-27
Key fundamentals
Cardinal Health, Inc.
Healthcare · Medical Distribution
| Market cap | $50.99B |
|---|---|
| Enterprise value | $56.52B |
| Trailing P/E | 30.50x |
| Forward P/E | 15.67x |
| EV / EBITDA | 13.32x |
| P / S (ttm) | 0.20x |
| Profit margin | 0.7% |
| Revenue growth | +5.8% |
| Earnings growth | +68.8% |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.22 | |
| Sector | +0.08 | |
| Technical | +0.04 | |
| Earnings | +0.00 | |
| Sentiment | -0.17 |
macro × 1.00 · 2026-09-27
Business overview
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Risk Metrics
| Beta vs SPX | 0.28 |
|---|---|
| Corr SPX | 0.17 |
| Annual vol | 26.7% |
| Annual ret | +37.4% |
| Sharpe | 1.40 |
| Max DD | -20.6% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $245.27 |
|---|---|
| High / Low | $275.00 / $215.00 |
| Median | $245.00 |
| Analysts | 15 |
| Strong Buy | 3 | |
|---|---|---|
| Buy | 12 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-04 | JP Morgan | → Neutral |
| 2026-05-01 | Wells Fargo | → Overweight |
| 2026-05-01 | TD Cowen | → Buy |
| 2026-05-01 | Citigroup | → Buy |
| 2026-04-28 | William Blair | → Outperform |
| 2026-04-08 | Evercore ISI Group | → Outperform |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-11 | Earnings Release, Reg FD Disclosure… | read |
| 2026-08-11 | Material Agreement, Termination of Agreement… | read |
| 2026-08-05 | Officer / Director Change | read |
| 2026-04-30 | Earnings Release, Reg FD Disclosure… | read |
| 2026-03-23 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-03-05 | Officer / Director Change | read |
| 2026-02-05 | Earnings Release, Reg FD Disclosure… | read |
| 2026-01-13 | Reg FD Disclosure, Exhibits | read |
| 2025-11-06 | Shareholder Vote | read |
| 2025-10-30 | Earnings Release, Reg FD Disclosure… | read |
| 2025-10-10 | Material Agreement, Exhibits | read |
| 2025-10-03 | Material Agreement, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Pitteroff Valerie Christine | Chief Human Resources Off | Grant | 2.61K | — |
| 2026-08-04 | Scherer Mary C. | Chief Accounting Officer | Grant | 2.61K | — |
| 2026-08-04 | Mayer Jessica L | Chief Legal/Compliance Of | Grant | 46.99K | — |
| 2026-08-04 | Mason Stephen M | CEO, GMPD Segment | Grant | 46.99K | — |
| 2026-08-04 | WEITZMAN DEBORAH | CEO, PSS Segment | Grant | 54.82K | — |
| 2026-08-04 | Alt Aaron E | Chief Financial Officer | Grant | 58.74K | — |
| 2026-08-04 | Greene Michelle D. | Chief Information Officer | Grant | 17.23K | — |
| 2026-08-04 | Hollar Jason M. | Chief Executive Officer | Grant | 187.97K | — |
| 2026-04-15 | Hall Patricia Hemingway | Grant | 381 | $79.18K | |
| 2026-02-27 | Greene Michelle D. | Chief Information Officer | Sell | 100 | $22.86K |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 10 |
| Top-5 share | 94.8% |
| HHI | 4,578 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $2.84B | 11.97M |
| Fidelity / FMR LLC | $490.86M | 2.07M |
| AQR Capital Management | $411.65M | 1.73M |
| Capital Research / Capital World | $226.34M | 952.75K |
| Renaissance Technologies | $130.68M | 550.10K |
| Citadel Advisors | $122.70M | 516.52K |
| Millennium Management | $70.78M | 297.93K |
| Bridgewater Associates | $31.38M | 132.08K |
| Norges Bank (Norway sovereign) | $1.40M | 5.90K |
| T. Rowe Price Group | $533.34K | 2.25M |
As of 2026-06-30
Dividends
| Yield (TTM) | 0.70% |
|---|---|
| $ / share (TTM) | $1.53 |
| 5y CAGR | +1.0% |
Annual dividend per share
| 2021 | $1.96 |
|---|---|
| 2022 | $1.98 |
| 2023 | $2.00 |
| 2024 | $1.51 |
| 2025 | $2.03 |
| 2026 | $1.02 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $758.74K | Department of Veterans Affairs | RADIOPHARMACEUTICALS |
| $741.88K | Department of Veterans Affairs | RADIOPHARMACEUTICAL ISOTOPES FUNDING DOCUMENT |
| $724.04K | Department of Veterans Affairs | RADIOPHARMACEUTICALS ORDER |
| $676.62K | Department of Veterans Affairs | VARIOUS NUCLEAR MED |
| $384.72K | Department of Veterans Affairs | MEDICATION CARVYKTI |
| $362.74K | Department of Veterans Affairs | NUC LAB BASE PLUS 4 OPTION YEARS DELIVERY. |
| $362.19K | Department of Defense | 4564107685!PHARM PRIME VENDOR FLEET |
| $307.11K | Department of Veterans Affairs | EMERGENCY QTY 1 TECCARTUS |
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $226.83B | +16.7% | |
| Gross profit | $6.87B | +15.1% | |
| Operating income | $1.24B | -0.5% | |
| Net income | $330.00M | +3.2% | |
| Cash from ops | $2.40B | +3.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $222.00 | $223.02 | $219.10 | $220.22 | 2.09M |
| Sep 24 | $222.08 | $225.37 | $221.95 | $222.62 | 3.48M |
| Sep 23 | $221.79 | $225.64 | $220.94 | $221.27 | 1.22M |
| Sep 22 | $227.17 | $228.44 | $221.21 | $222.04 | 2.78M |
| Sep 21 | $225.28 | $227.58 | $223.54 | $225.75 | 1.19M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →